A Phase 3 interventional study of subcutaneous Enoxaparin and standard of care in Fetal Growth Retardation, Prematurity and Pre-Eclampsia, sponsored by Centro Hospitalar de Lisboa Central. Enrolling by invitation at 1 site in Portugal. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-13.
Sponsored by Centro Hospitalar de Lisboa Central · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Early fetal growth restriction (FGR) is associated with considerable fetal and neonatal morbimortality. Placental thrombosis, infarcts and hypercoagulability are frequently seen in these pregnancies, suggesting a role for the activation of the coagulation cascade in the genesis of FGR. Patients will be randomized for low-molecular weight heparin or standard of care, and the outcomes of both arms (gestational age at delivery, gestational and fetal morbidity) will be compared.
FGR is the second leading cause of perinatal mortality, being associated with approximately 30% of stillbirths. Early FGR is associated with substantial disturbances of placental implantation and fetal hypoxia, which requires fetal cardiovascular adaptation. Both maternal and fetal Doppler alterations are present, allowing for risk stratification and monitoring. Although the precise etiology for FGR due to placental causes is unknown, placental thrombosis, infarcts and hypercoagulability are frequently seen, suggesting a role for the activation of the coagulation cascade in the genesis of FGR. Currently, the management of early FGR is limited to the monitoring of fetal Doppler parameters until the risks for preterm delivery outweight the benefits of ongoing monitoring. As such, there is a special need for effective preventive and therapeutic interventions that improve the outcomes. Low molecular weight heparin (LMWH), for its anticoagulant and anti-inflammatory properties has been suggested as a possible therapeutic agent in this setting. The investigators will randomize the participants to two intervention arms in a one-to-one ratio, using a computer generated randomization program. The randomization will be stratified for gestational age at diagnosis of FGR (22 to 26 weeks and >26 to 32 weeks). The experimental group will be administered enoxaparin subcutaneous injections (40 mg, 4000 IU daily) and the control group will be provided standard of care. Both groups will start intervention immediately after the diagnosis of FGR, and will continue it until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.
This study's planned enrollment of 12 is below the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.
Browse Fetal Growth Retardation studies →Centro Hospitalar de Lisboa Central is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enoxaparin subcutaneous injections
Drug: subcutaneous Enoxaparin
Obsteric standard of care
Other: standard of care
Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
Also known as: experimental
Obsteric standard of care.
Gestational age at delivery
Best assessment of the time of gestation, either by first trimester sonography, last menstrual day or day of implantation of in vitro conception product
Time frame: day of delivery
Neonatal birtweight and birthweight centile
Weight at birth of the newborn (in grams) and respective percentile
Time frame: day of delivery
Newborn Apgar Score in the 5th minute
Newborn Apgar score in the 5th minute, assessed by a nurse or pediatrician
Time frame: day of delivery
Newborn Umbilical Artery pH
pH of the umbilical artery, assessed immediately after delivery
Time frame: day of delivery
Stillbirth, neonatal intensive care admission and duration of admission
A composite outcome of severe neonatal morbidity (evidence of one or more of: intraventricular hemorrhage grade 3 or 4; cystic periventricular leukomalacia; chronic lung disease; retinopathy of prematurity requiring treatment; necrotizingenterocolitis requiring surgery
Time frame: from randomization up to 1 year after delivery
Maternal and fetal Doppler parameters
Pulsatility index (PI) of the uterine arteries, PI anddiastolic flow in the umbilical artery, PI in the middle cerebral artery, cerebro-placental ratio, ductusvenosus PI and a wave
Time frame: from randomization to delivery
Placental pathology
Percentage of placenta occupied by fibrosis or infarcts
Time frame: day of delivery
Sflt1-PLGF ratio
Evolution of Sflt1-PLGF ratio from diagnosis of FGR to delivery
Time frame: from randomization to delivery
Syncytiotrophoblast membrane extracellular vesicles (STB-EV)
Protein and genetic composition
Time frame: from randomization up to 1 week after delivery
Gestational hypertension or preeclampsia; placental abruption
Pregnancy induced hypertension, preeclamspia,HELLP syndrome
Time frame: from randomization up to 1 week after delivery
Antepartum hemorrhage; maternal thrombocytopenia (platelets < 100 000 x 10 9/L); postpartum hemorrhage
Hemorrhage, bruising,pain
Time frame: from randomization up to 1 week after delivery
Mode and indication for delivery
As spontaneous vaginal birth, operative vaginal birth (forceps orvacuum/ventouse), or cesarean section. For induced labor or planned cesarean section, theindication for scheduling the delivery will be documented (e.g., gestational age, maternal or fetalindications). In cases of operative vaginal or cesarean delivery, the indication for intervention willbe specified (e.g., non-reassuring fetal status, labor dystocia).
Time frame: from randomization up to 48h after delivery
Plan to share: No
Started Jul 2022 (actual). Primary completion is estimated for Jul 2026, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enoxaparin
Centro Hospitalar de Lisboa Central